PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2020.12462021533695-702Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)Jiyun Lee, Seock-Ah Im, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Yeon Hee Parkhttp://e-crt.org/upload/pdf/crt-2020-1246.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2020.1246, http://e-crt.org/upload/pdf/crt-2020-1246.pdf
Breast Cancer Research and Treatment10.1007/s10549-019-05439-x20191792371-376Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patientsHugo Herrscher, Michel Velten, Julie Leblanc, Michal Kalish-Weindling, Cathie Fischbach, Delphine Exinger, Xavier Pivot, Thierry Petithttp://link.springer.com/content/pdf/10.1007/s10549-019-05439-x.pdf, http://link.springer.com/article/10.1007/s10549-019-05439-x/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10549-019-05439-x.pdf
Clinical Breast Cancer10.1016/j.clbc.2019.02.0042019194e519-e521Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor–Positive/Human Epidermal Receptor 2–Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic CostsJacopo Giuliani, Andrea Bonettihttps://api.elsevier.com/content/article/PII:S1526820918308036?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820918308036?httpAccept=text/plain
Breast Cancer and Surgery10.5772/intechopen.765782018Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast CancerFatma Senhttp://www.intechopen.com/download/pdf/61285
Annals of Oncology10.1093/annonc/mdz394.013201930v862Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer from the YoungPearl phase ll trial (KCSG-BR 15-10, NCT02592746)S. Lee, Y.H. Park, S.-A. Im, K.H. Jung, I.H. Park, S.Y. Kang, J.H. Kim, G.M. Kim, K.-E. Lee, H. Ahn, M.H. Lee, H.J. Kim, S. Kohhttps://api.elsevier.com/content/article/PII:S092375341960373X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S092375341960373X?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz394.013/30082456/mdz394.013.pdf
The Breast10.1016/j.breast.2018.08.033201841S11-S12Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studiesMassimo Cristofanilli, Nadia Harbeck, Hope Rugo, Aurelio Castrellon, Anyl A. Joy, Sunil Verma, Seock-Ah Im, Shrividya Iyer, Kathy Puyana, Eric Gauthier, Xin Huang, Cynthia Huang Bartlett, Sibylle Loibl, Richard S. Finnhttps://api.elsevier.com/content/article/PII:S0960977618301760?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977618301760?httpAccept=text/plain
Clinical Breast Cancer10.1016/j.clbc.2018.09.0022019191e186-e194Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor–Positive/HER2-Negative Metastatic Breast CancerGeoffrey Alan Watson, Oana Deac, Razia Aslam, Richard O'Dwyer, Antonia Tierney, Sue Sukor, John Kennedyhttps://api.elsevier.com/content/article/PII:S152682091830507X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S152682091830507X?httpAccept=text/plain
Breast Cancer Research and Treatment10.1007/s10549-019-05190-320191753775-779Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancerBingnan Zhang, Elisa F. Longhttp://link.springer.com/content/pdf/10.1007/s10549-019-05190-3.pdf, http://link.springer.com/article/10.1007/s10549-019-05190-3/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10549-019-05190-3.pdf
Annals of Oncology10.1093/annonc/mdw365.45201627vi82Is the overall survival after hormone therapy for hormone-receptor-positive, HER2-negative metastatic breast cancer still better than for triple-negative metastatic breast cancer?J. Watanabe, T. Hayashi, Y. Tadokoro, S. Nishimura, K. Takahashihttps://api.elsevier.com/content/article/PII:S0923753419438970?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419438970?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/27/suppl_6/266P/19449441/mdw365.45.pdf
European Journal of Cancer10.1016/s0959-8049(20)30546-32020138S7-S8Predictors of efficacy in patients (pts) with hormone receptor–positive/ human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3H. Rugo, M. Cristofanilli, S. Loibl, N. Harbeck, A. Demichele, H. Iwata, Y.H. Park, A. Brufsky, K.Puyana Theall, X. Huang, L. McRoy, E. Bananis, N.C. Turnerhttps://api.elsevier.com/content/article/PII:S0959804920305463?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804920305463?httpAccept=text/plain